Report #2854183

Overview

Sex

Female

Age

Age unknown

State

IL

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (2)

Symptom narrative

Incorrect Site of Administration; Local reaction; This non-serious case was reported by a nurse via call center representative and described the occurrence of incorrect route of product administration in a 11-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number X449Y, expiry date 20-OCT-2026) for prophylaxis. Co-suspect products included Men ACWY-CRM NVS (Menveo) (batch number GB73Y, expiry date 31-JUL-2026) for prophylaxis. On an unknown date, the patient received Boostrix (right arm) and Menveo (right arm). On an unknown date, an unknown time after receiving Boostrix and Menveo, the patient experienced incorrect route of product administration (Verbatim: Incorrect Site of Administration) and local reaction (Verbatim: Local reaction). The outcome of the incorrect route of product administration was not applicable and the outcome of the local reaction was unknown. It was unknown if the reporter considered the local reaction to be related to Boostrix, Boostrix Pre-Filled Syringe Device and Menveo. It was unknown if the company considered the local reaction to be related to Boostrix, Boostrix Pre-Filled Syringe Device and Menveo. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 05-AUG-2025 The reporter reported that patient came over the weekend and one of our staff members administered the Menveo vaccine but she, that was administered in the arm but, approximately 3 to 4 inches below the deltoid, it did not hit anywhere in the deltoid, there was a minor local reaction then reporters concern was would the vaccine be absorbed correctly or would that need to be repeat. Boostrix was administered in the same arm, the same day and same place, which led to incorrect route of administration.